John Mendlein, Director at FATE THERAPEUTICS INC (FATE), bought 249,358 shares at $5.43 ($1.4M) on 2023-01-13, disclosed to the SEC on 2023-01-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.67 | 88,048 | $499K | 35.8% |
| 2 | $5.67 | 88,048 | $499K | 35.8% |
| 3 | $5.43 | 36,631 | $199K | 14.2% |
| 4 | $5.43 | 36,631 | $199K | 14.2% |
| Total | $5.60 avg | 249,358 | $1.4M | 100% |
| Filing → |
| LIFE | BUY | 2018-12-26 | $102K | — | Filing → |
| LIFE | BUY | 2017-09-05 | $200K | — | Filing → |
| LIFE | BUY | 2017-04-26 | $372 | — | Filing → |